NCT06852768View on ClinicalTrials.gov

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
oGHVD
Interventions
BIOLOGICAL

d-MAPPS

Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.

BIOLOGICAL

Placebo

Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.

OTHER

PI and Patient Masked

Both the PI and the participant are masked on the drug administered.

Trial Locations (4)

34684

RECRUITING

Regenerative Ocular Immunobiologics, LLC., Palm Harbor

90210

RECRUITING

Beverly Hills Institute of Ophthalmology, Beverly Hills

92648

RECRUITING

Beach Eye Medical Group, Huntington Beach

02215

RECRUITING

Eyewell, LLC., Boston

All Listed Sponsors
lead

Regenerative Ocular Immunobiologics LLC

INDUSTRY